Last reviewed · How we verify

NCT06152497

The Role of Histamine in Muscle Protein Synthesis Following Resistance Training

Recruiting now NA Last updated 13 December 2023
What this trial tests

NA trial testing Placebo in Histamine in 50 participants. Currently enrolling.

Timeline
1 September 2023
Primary endpoint
31 December 2026
31 December 2026

Quick facts

Lead sponsorUniversity Ghent
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposebasic science
Enrollment50
Start date1 September 2023
Primary completion31 December 2026
Estimated completion31 December 2026
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

University Ghent

Who can join

Adults 18 to 45, male only, with Histamine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Blocking histamine H1/H2 receptors blunts chronic endurance training adaptations. The current study addresses the following research question: "What is the influence of histamine H1 signaling on training adaptations following ten weeks of resistance training in human skeletal muscle." Results from this study will yield more insights into the molecular mechanisms of adaptations to exercise training.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Histamine

Currently open trials in the same condition.

Other University Ghent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06152497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing